These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 25267954)

  • 1. Melanoma and non-melanoma skin cancer in inflammatory bowel disease patients following tumor necrosis factor-α inhibitor monotherapy and in combination with thiopurines: analysis of the Food and Drug Administration Adverse Event Reporting System.
    McKenna MR; Stobaugh DJ; Deepak P
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):267-71. PubMed ID: 25267954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Infectious complications of TNF-α inhibitor monotherapy versus combination therapy with immunomodulators in inflammatory bowel disease: analysis of the Food and Drug Administration Adverse Event Reporting System.
    Deepak P; Stobaugh DJ; Ehrenpreis ED
    J Gastrointestin Liver Dis; 2013 Sep; 22(3):269-76. PubMed ID: 24078983
    [TBL] [Abstract][Full Text] [Related]  

  • 3. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-α) inhibitors: results of the REFURBISH study.
    Deepak P; Sifuentes H; Sherid M; Stobaugh D; Sadozai Y; Ehrenpreis ED
    Am J Gastroenterol; 2013 Jan; 108(1):99-105. PubMed ID: 23032984
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of tumor necrosis factor-α inhibitors on drug-induced pancreatitis in inflammatory bowel disease.
    Stobaugh DJ; Deepak P
    Ann Pharmacother; 2014 Oct; 48(10):1282-7. PubMed ID: 24982311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of malignancies in patients with inflammatory bowel disease treated with thiopurines or anti-TNF alpha antibodies.
    Beigel F; Steinborn A; Schnitzler F; Tillack C; Breiteneicher S; John JM; Van Steen K; Laubender RP; Göke B; Seiderer J; Brand S; Ochsenkühn T
    Pharmacoepidemiol Drug Saf; 2014 Jul; 23(7):735-44. PubMed ID: 24788825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neurological events with tumour necrosis factor alpha inhibitors reported to the Food and Drug Administration Adverse Event Reporting System.
    Deepak P; Stobaugh DJ; Sherid M; Sifuentes H; Ehrenpreis ED
    Aliment Pharmacol Ther; 2013 Aug; 38(4):388-96. PubMed ID: 23802849
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maternal and foetal adverse events with tumour necrosis factor-alpha inhibitors in inflammatory bowel disease.
    Deepak P; Stobaugh DJ
    Aliment Pharmacol Ther; 2014 Nov; 40(9):1035-43. PubMed ID: 25164260
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of melanoma and non-melanoma skin cancer in ulcerative colitis patients treated with thiopurines: a nationwide retrospective cohort.
    Abbas AM; Almukhtar RM; Loftus EV; Lichtenstein GR; Khan N
    Am J Gastroenterol; 2014 Nov; 109(11):1781-93. PubMed ID: 25244964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of melanoma and nonmelanoma skin cancer among patients with inflammatory bowel disease.
    Long MD; Martin CF; Pipkin CA; Herfarth HH; Sandler RS; Kappelman MD
    Gastroenterology; 2012 Aug; 143(2):390-399.e1. PubMed ID: 22584081
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alleged isotretinoin-associated inflammatory bowel disease: disproportionate reporting by attorneys to the Food and Drug Administration Adverse Event Reporting System.
    Stobaugh DJ; Deepak P; Ehrenpreis ED
    J Am Acad Dermatol; 2013 Sep; 69(3):393-8. PubMed ID: 23683730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased risk for nonmelanoma skin cancers in patients who receive thiopurines for inflammatory bowel disease.
    Peyrin-Biroulet L; Khosrotehrani K; Carrat F; Bouvier AM; Chevaux JB; Simon T; Carbonnel F; Colombel JF; Dupas JL; Godeberge P; Hugot JP; Lémann M; Nahon S; Sabaté JM; Tucat G; Beaugerie L;
    Gastroenterology; 2011 Nov; 141(5):1621-28.e1-5. PubMed ID: 21708105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn's disease.
    Osterman MT; Sandborn WJ; Colombel JF; Robinson AM; Lau W; Huang B; Pollack PF; Thakkar RB; Lewis JD
    Gastroenterology; 2014 Apr; 146(4):941-9. PubMed ID: 24361468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of thiopurines in the treatment of inflammatory bowel disease is associated with an increased risk of non-melanoma skin cancer in an at-risk population: a cohort study.
    Setshedi M; Epstein D; Winter TA; Myer L; Watermeyer G; Hift R
    J Gastroenterol Hepatol; 2012 Feb; 27(2):385-9. PubMed ID: 21793904
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of thiopurine and anti-TNF therapy in lymphoma in inflammatory bowel disease.
    Herrinton LJ; Liu L; Weng X; Lewis JD; Hutfless S; Allison JE
    Am J Gastroenterol; 2011 Dec; 106(12):2146-53. PubMed ID: 22031357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease.
    Lemaitre M; Kirchgesner J; Rudnichi A; Carrat F; Zureik M; Carbonnel F; Dray-Spira R
    JAMA; 2017 Nov; 318(17):1679-1686. PubMed ID: 29114832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between thiopurine use and nonmelanoma skin cancers in patients with inflammatory bowel disease: a meta-analysis.
    Ariyaratnam J; Subramanian V
    Am J Gastroenterol; 2014 Feb; 109(2):163-9. PubMed ID: 24419479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Corticosteroids and Thiopurines, But Not Tumor Necrosis Factor Antagonists, are Associated With Cytomegalovirus Reactivation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis.
    Shukla T; Singh S; Tandon P; McCurdy JD
    J Clin Gastroenterol; 2017; 51(5):394-401. PubMed ID: 27875356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapy.
    Marzano AV; Borghi A; Meroni PL; Crosti C; Cugno M
    Autoimmunity; 2014 May; 47(3):146-53. PubMed ID: 24437626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel disease.
    Moran GW; Lim AW; Bailey JL; Dubeau MF; Leung Y; Devlin SM; Novak K; Kaplan GG; Iacucci M; Seow C; Martin L; Panaccione R; Ghosh S
    Aliment Pharmacol Ther; 2013 Nov; 38(9):1002-24. PubMed ID: 24099467
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The risk of non-melanoma skin cancer in New Zealand in inflammatory bowel disease patients treated with thiopurines.
    Bahi M; Walmsley RS; Gray AR; Young D; Hobbs CE; Aluzaite K; Schultz M
    J Gastroenterol Hepatol; 2018 May; 33(5):1047-1052. PubMed ID: 29105142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.